Status:
COMPLETED
Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this Post-Marketing Study is to monitor the safety of a novel smoking cessation drug Varenicline (Champix™) 0.5 mg and 1 mg tablets as used in clinical practice for 12 weeks a...
Detailed Description
The study will enroll smoking patients.
Eligibility Criteria
Inclusion
- Smoking adults aged ≥ 18 years intending to quit tobacco use who are prescribed Varenicline (Champix™) by their Physicians and those who are prescribed with Varenicline (Champix™) for the first time.
Exclusion
- Subjects in whom varenicline (Champix™) may be taken in a manner that is not according to the approved local product document.
- Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception
- Subjects with known hypersensitivity to varenicline.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT00794365
Start Date
July 1 2008
End Date
November 1 2009
Last Update
December 20 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.